» Authors » Mark Nagel

Mark Nagel

Explore the profile of Mark Nagel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 187
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Anderson S, Seto E, Chau D, Lee B, Vail A, Ding S, et al.
Biotechnol Bioeng . 2023 Oct; 121(2):757-770. PMID: 37902763
The most straightforward method to increase monoclonal antibody (mAb) product yield is to complete the purification process in less steps. Here, three different fiber chromatographic devices were implemented using a...
2.
Moldt B, Chandrashekar A, Borducchi E, Nkolola J, Stephenson H, Nagel M, et al.
PLoS Pathog . 2022 Apr; 18(4):e1010467. PMID: 35452496
A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and...
3.
Bekerman E, Hesselgesser J, Carr B, Nagel M, Hung M, Wang A, et al.
Antimicrob Agents Chemother . 2019 Sep; 63(11). PMID: 31501143
Antiretroviral therapy (ART) limits human immunodeficiency virus 1 (HIV-1) replication but does not eliminate the long-lived reservoir established shortly after viral acquisition. A successful HIV cure intervention necessitates either elimination...
4.
Wachtel H, Nagel M, Engel M, El Azzi G, Sharma A, Suggett J
Respir Med . 2018 Apr; 137:181-190. PMID: 29605203
Background: When characterizing inhalation products, a comprehensive assessment including in vitro, pharmacokinetic (PK), and clinical data is required. We conducted a characterization of tiotropium Respimat when administered with AeroChamber Plus...
5.
Dissanayake S, Nagel M, Falaschetti E, Suggett J
Pulm Pharmacol Ther . 2017 Oct; 48:179-184. PMID: 29024795
Introduction: The European Medicines Agency (EMA) requires that a specific valved holding chamber (VHC) is designated for use with a given pressurised metered dose inhaler (pMDI). No other regulatory authorities...
6.
Mitchell J, Suggett J, Nagel M
AAPS PharmSciTech . 2016 May; 17(4):787-804. PMID: 27173990
Current pharmacopeial methods for in vitro orally inhaled product (OIP) performance testing were developed primarily to support requirements for drug product registration and quality control. In addition, separate clinical studies...
7.
Buchheit M, Cholley Y, Nagel M, Poulos N
Int J Sports Physiol Perform . 2015 Dec; 11(6):721-726. PMID: 26638728
Purpose: To examine the effect of body mass (BM) on eccentric knee-flexor strength using the Nordbord and offer simple guidelines to control for the effect of BM on knee-flexor strength....
8.
Kamalaporn H, Leung K, Nagel M, Kittanakom S, Calvieri B, Reithmeier R, et al.
Pediatr Pulmonol . 2013 Jul; 49(6):574-80. PMID: 23843366
Background: Aerosolized liposomal Amphotericin B may reduce the incidence of invasive pulmonary Aspergillosis in adults with chemotherapy-induced prolonged neutropenia with less nephrotoxicity. The breath-actuated AeroEclipse® BAN nebulizer is very efficient...
9.
Myrdal P, Mogalian E, Mitchell J, Nagel M, Wright C, Kiser B, et al.
J Aerosol Med . 2007 Jan; 19(4):543-54. PMID: 17196082
Pharmaceutical aerosol size distribution analysis based on multi-stage inertial impaction is well accepted, though laborious. The TSI 3306 Impactor Inlet/3321 time-of-flight (TOF) Aerodynamic Particle Size Analyzer (APS) has been evaluated...
10.
Camenisch G, Pisabarro M, Sherman D, Kowalski J, Nagel M, Hass P, et al.
J Biol Chem . 2002 Mar; 277(19):17281-90. PMID: 11877390
The angiopoietin family of secreted factors is functionally defined by the C-terminal fibrinogen (FBN)-like domain, which mediates binding to the Tie2 receptor and thereby facilitates a cascade of events ultimately...